Phase II trial of INNO 206 as second-line therapy in patients with advanced gastric cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2011
At a glance
- Drugs Aldoxorubicin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors CytRx Corporation
- 29 Apr 2011 Status changed from planning to unconfirmed (trial does not appear to have been initiated and CytRx has refocussed on trials in pancreatic cancer and soft tissue sarcoma).
- 07 Apr 2009 New trial record.